179 related articles for article (PubMed ID: 35782609)
1. Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3.
Lee NC; Chien YH; Wang CH; Wong SL; Peng SS; Tsai FJ; Hwu WL
Mol Genet Metab Rep; 2022 Jun; 31():100867. PubMed ID: 35782609
[TBL] [Abstract][Full Text] [Related]
2. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.
Kleytman N; Ruan J; Ruan A; Zhang B; Murugesan V; Lin H; Guo L; Klinger K; Mistry PK
Mol Genet Metab Rep; 2021 Dec; 29():100798. PubMed ID: 34485083
[TBL] [Abstract][Full Text] [Related]
3. Glucosylsphingosine is a key biomarker of Gaucher disease.
Murugesan V; Chuang WL; Liu J; Lischuk A; Kacena K; Lin H; Pastores GM; Yang R; Keutzer J; Zhang K; Mistry PK
Am J Hematol; 2016 Nov; 91(11):1082-1089. PubMed ID: 27441734
[TBL] [Abstract][Full Text] [Related]
4. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-life Unicentric Experience.
Duminuco A; Fazio M; Grasso S; Gullo L; Riccobene C; Calafiore V; Markovic U; Di Raimondo F; Giuffrida G
Clin Ther; 2023 Nov; 45(11):1105-1110. PubMed ID: 37722956
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients.
Malinová V; Poupětová H; Řeboun M; Dvořáková L; Reichmannová S; Švandová I; Murgašová L; Kasper DC; Magner M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833892
[TBL] [Abstract][Full Text] [Related]
7. Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy.
Istaiti M; Becker-Cohen M; Dinur T; Revel-Vilk S; Zimran A
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362492
[TBL] [Abstract][Full Text] [Related]
8. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
Sidhu K; Boyd SK; Khan A
Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM; Charrow J; Lukina E; Mistry PK; Foster MC; Peterschmitt MJ
Genet Med; 2023 Feb; 25(2):100329. PubMed ID: 36469032
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
Elife; 2023 May; 12():. PubMed ID: 37249220
[TBL] [Abstract][Full Text] [Related]
11. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.
Serrano-Gonzalo I; de Frutos LL; Lahoz-Gil C; Delgado-Mateos F; Fernández-Galán MÁ; Morales-Conejo M; Calle-Gordo MV; Ibarretxe-Gerediaga D; Madinaveitia-Ochoa A; Albarracin-Arraigosa A; Balanzat-Muñoz J; Correcher-Medina P; García-Frade LJ; Hernández-Rivas JM; Labbadia F; López-Dupla JM; Lozano-Almela ML; Mora-Casterá E; Noya-Pereira MS; Ruíz-Guinaldo MÁ; Del Mar Tormo-Díaz M; Vitoria-Miñana I; Arévalo-Vargas I; Andrade-Campos M; Giraldo P
Orphanet J Rare Dis; 2023 Dec; 18(1):390. PubMed ID: 38102667
[TBL] [Abstract][Full Text] [Related]
12. Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy.
Kim YM; Shin DH; Park SB; Cheon CK; Yoo HW
BMC Med Genet; 2017 May; 18(1):55. PubMed ID: 28506293
[TBL] [Abstract][Full Text] [Related]
13. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS).
Hughes DA; Deegan P; Giraldo P; Göker-Alpan Ö; Lau H; Lukina E; Revel-Vilk S; Scarpa M; Botha J; Gadir N; Zimran A;
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079085
[TBL] [Abstract][Full Text] [Related]
14. Long-term eliglustat treatment of Gaucher patients over up to 10 years in Vienna.
Stulnig TM
Wien Klin Wochenschr; 2022 Jun; 134(11-12):471-477. PubMed ID: 35412052
[TBL] [Abstract][Full Text] [Related]
15. Glucosylsphingosine (Lyso-Gb
Gayed MM; Jung SH; Huggins E; Rodriguez-Rassi E; DeArmey S; Kishnani PS; Stiles AR
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499264
[TBL] [Abstract][Full Text] [Related]
16. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
17. Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.
Peterschmitt MJ; Foster MC; Ji AJ; Zajdel MB; Cox GF
Mol Genet Metab; 2023 Mar; 138(3):107527. PubMed ID: 36739645
[TBL] [Abstract][Full Text] [Related]
18. Abdominal lymphadenopathy in children with Gaucher disease: Relation to disease severity and glucosylsphingosine.
Tantawy AAG; Adly AAM; Atif HM; Madkour SS; Salah NY
Pediatr Hematol Oncol; 2022 May; 39(4):304-317. PubMed ID: 34668825
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for oral treatment for adult patients with type 1 Gaucher disease.
Torralba-Cabeza MÁ; Morado-Arias M; Pijierro-Amador A; Fernández-Canal MC; Villarrubia-Espinosa J
Rev Clin Esp (Barc); 2022 Jun; ():. PubMed ID: 35676195
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.
Balwani M; Burrow TA; Charrow J; Goker-Alpan O; Kaplan P; Kishnani PS; Mistry P; Ruskin J; Weinreb N
Mol Genet Metab; 2016 Feb; 117(2):95-103. PubMed ID: 26387627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
